US EditionSanofi Sells 50% Stake in Opella to CD&R, Establishing Independent Global Consumer Healthcare Champion
6 Articles
6 Articles
On Wednesday 30 April, Sanofi finalized the sale of Opella, the company producing the famous medicine box, to the CD&R investment fund. "Opella is now an independent company", confirmed the management, formalizing the end of this transaction, announced in October and which had provoked opposition from politicians and trade unions. The announcement took place just before the general meeting of Sanofi shareholders, Wednesday afternoon in Paris as …
At the end of the operation, the French pharmaceutical laboratory retained 48.2% of the company's shares, now 50% owned by the US investment fund CD&R.
On 30 April 2025, Sanofi, a mastodon of the pharmaceutical industry, formalized the divestiture of 50 % of its subsidiary Opella, which manufactures the doliprane, to the US fund Clayton, Dubilier & Rice (CD&R). A transaction that questions industrial sovereignty, employment, and the role of the state in health affairs. The doliprane under American flag: a sale at the price fort The announcement fell with the regularity of a cutlet: Sanofi took …
Sanofi Sells 50% Stake in Opella to CD&R, Establishing Independent Global Consumer Healthcare Champion
Sanofi Sells 50% Stake in Opella to CD&R, Establishing Independent Global Consumer Healthcare Champion (IN BRIEF) Sanofi has completed the sale of a 50.0% controlling stake in its consumer healthcare division, Opella, to CD&R, creating a global leader in consumer healthcare. Sanofi retains a significant 48.2% stake, while Bpifrance will hold 1.8% and join Opella’s Board. With an annual portfolio of iconic brands like Allegra, Doliprane, and Dulc…
Sanofi has completed the sale of a majority shareholding from Opella to Clayton, Dubilier & Rice (CD&R), a step that makes the company an independent entity. According to a statement, Sanofi retains a significant shareholding of 48.2%, while Bpifrance owns 1.8%. This change in the stockholding structure marks a turning point in Opella’s operation, which will now be supported by CD&R for its future development. Opella, which is ranked as the thir…
Doliprane: the flagship drug is changing its flag, Sanofi takes 10 billion euros when selling its subsidiary Opella, now controlled by an American fund.
Coverage Details
Bias Distribution
- 50% of the sources lean Left, 50% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
